Early interim CT is the strongest prognostic factor in metastatic gastrointestinal neuroendocrine carcinomas (GI-NEC): results from the French NECTAR study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Metastatic gastrointestinal neuroendocrine carcinoma (mGI-NEC) is known for its aggressive natural course with a short median overall survival (mOS). Currently, clinical tools guiding treatment strategy are lacking. We aimed to evaluate the prognostic impact of early depth of response (DpR). Patients and methods We conducted a retrospective study across 13 French centers. Consecutive patients with mGI-NEC treated with a platinum salt as first-line therapy between January 2010 and December 2023 were included. DpR was defined as the relative change in the sum of the largest diameters of target lesions on the first radiological assessment compared with baseline. Patients were stratified into 4 groups: (VGPR) (−100% to −60%); (PR) (−59% to −31%); (SD) (−30% to 0%); and (ITV) (0% or more). Multivariate Cox models, E-Values, bootstrap, and restrictive analyses were computed. Results Two hundred and twenty-nine patients with an mGI-NEC (colorectal for 28%, pancreatic for 24%) were included. mOS was 9.4 months. Seventy-five patients (33%) presented with ITV, 52 patients (23%) with SD, 70 patients (31%) with PR, and 32 patients (14%) with VGPR at first assessment (median of 2.1 months). mOS steadily decreased with the DpR. With SD as a reference, multivariate HR was 0.31 (0.19-0.50) for VGPR, 0.39 (0.27-0.58) for PR, and 2.17 (1.47-3.20) for ITV. Results of all sensitivity analyses were identical. Conclusion Early DpR was independently associated with OS and provided stronger prognostic discrimination than baseline factors. Prospective studies are warranted to determine whether DpR can guide risk-adapted treatment strategies.
Source: ESMO Gastrointestinal Oncology
Institutions: Hôpitaux Universitaires de Strasbourg, Centre Hospitalier Universitaire Amiens-Picardie, Centre Hospitalier Universitaire de Reims, Université de Reims Champagne-Ardenne, Hôpital Européen Georges-Pompidou, CHU Dijon Bourgogne, Centre Hospitalier Universitaire de Clermont-Ferrand, Centre Hospitalier Universitaire de Besançon, Institut Jean Godinot, Centre Hospitalier de la Côte Basque, Centre Hospitalier Universitaire de Rennes, Centre Hospitalier de Mulhouse, Inserm, Établissement Français du Sang, Université Marie et Louis Pasteur, Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, Institut Strauss, Centre Hospitalier Régional et Universitaire de Nancy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W7235673339
